8-KEarnings & ResultsLeadership ChangesFinancial Events+1

BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Feb 10, 2010)

Filed February 10, 2010For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on February 10, 2010, detailing its fourth quarter and full-year 2009 financial results and providing initial guidance for 2010. The company also announced significant restructuring initiatives and management changes aimed at enhancing operational efficiency and long-term growth. These restructuring efforts are expected to yield substantial annual pre-tax operating expense reductions once fully implemented by 2011. The restructuring plan, approved by the Board of Directors on February 6, 2010, involves integrating the Cardiovascular and Cardiac Rhythm Management (CRM) businesses, centralizing R&D, and streamlining other business units and corporate functions. This plan anticipates the elimination of 1,000 to 1,300 positions and is estimated to incur pre-tax charges between $180 million and $200 million, with a significant portion expected in 2010. These charges will cover termination benefits, asset write-offs, and other restructuring-related expenses.

Key Highlights

  • 1Boston Scientific announced its Q4 and Full Year 2009 financial results and provided initial 2010 guidance.
  • 2A significant restructuring plan, the '2010 Plan', was approved on February 6, 2010.
  • 3The 2010 Plan aims to reduce annual pre-tax operating expenses by $200 million to $250 million once completed in 2011.
  • 4The restructuring involves integrating Cardiovascular and CRM businesses, centralizing R&D, and other organizational changes.
  • 5Approximately 1,000 to 1,300 positions are expected to be eliminated.
  • 6Total pre-tax charges for the restructuring are estimated between $180 million and $200 million, with $140-160 million expected in 2010.
  • 7Key management promotions (Leno, Capello, Colen) and one executive departure (McFaul) were announced as part of the restructuring.

Frequently Asked Questions

The 2010 Plan includes integrating the Cardiovascular and Cardiac Rhythm Management (CRM) businesses, centralizing the Company’s R&D organization, and restructuring other businesses, regions, corporate functions, and product franchises. The goal is to drive innovation, accelerate profitable growth, and increase accountability and shareholder value.

The Company estimates total pre-tax charges of approximately $180 million to $200 million for the 2010 Plan, with $140 million to $160 million expected in 2010. These charges cover termination benefits, asset write-offs, and other restructuring expenses. Once completed in 2011, the plan is projected to reduce annual pre-tax operating expenses by $200 million to $250 million.

Effective March 1, 2010, Sam Leno was promoted to EVP and Chief Operations Officer, and Jeffrey Capello to EVP and Chief Financial Officer. Fred Colen was promoted to EVP and Chief Technology Officer effective February 10, 2010. David McFaul's position as Senior Vice President, International, was eliminated due to the closure of the International Headquarters.

This 8-K filing primarily announces that Boston Scientific issued a press release on February 10, 2010, detailing its financial results for the fourth quarter and full year ended December 31, 2009, and provides guidance for 2010. The press release itself is furnished as an exhibit (Exhibit 99.1) to this 8-K, and investors would need to refer to that exhibit for the specific financial results.